Track topics on Twitter Track topics that are important to you
Insulet to Host Three Educational Events at the AADE Conference in Indianapolis
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced several educational programs to help health care providers better connect with and treat their patients living with diabetes. Insulet will exhibit at the 2017 American Association of Diabetes Educators (AADE) Conference in Indianapolis, Indiana from August 3rd to August 5th. The Company will exhibit at booth #1311 and will also conduct Omnipod product demonstrations and a “Pod Challenge”, which will include a donation to AADE for each booth visitor who wears a demo Pod. Insulet will also host three interactive educational programs:
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170802006488/en/
To further drive Insulet’s growing product pipeline, the Company recently opened its “Innovation Center of Excellence” located in San Diego, California, a global hub for technology innovation. This facility has attracted local talent with vast expertise in Internet of Things, cloud-based technologies, mobile devices and cyber security. This growing team is driving Insulet’s mission to improve the lives of people living with diabetes through patient-centric innovation.
“Insulet is developing technologies and solutions that promote successful diabetes management for people with diabetes, as well as their health care providers,” said Dr. Aiman Malek, Senior Vice President of Advanced Technology and Engineering. “Our focus on integrating a user’s smartphone into our next-generation technology is just one example of how we are developing technology to simplify diabetes management and demonstrates our dedication to provide a truly innovative and differentiated product platform.”
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2017 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations and Media Contact:
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...